VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma (NCT04433156) | Clinical Trial Compass
CompletedPhase 2
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
China26 participantsStarted 2020-04-22
Plain-language summary
This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Bortezomib and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age between 18 to 70 years old (including 18 and 70)
✓. Diagnosed as marginal zone lymphoma
✓. No receiving chemotherapy before enrollment
✓. Indications for treatment: 1) symptoms related to tumor; 2) end-organ function damage; 3) large mass; 4) continuous or rapid progress of disease; 5) patient's willingness
✓. Having at least one measurable lesions
✓. World health organization-Eastern Cooperative Oncology Group Performance tatus (ECOG) 0-1
✓. Life expectancy no less than 3 months
✓. enough main organ function
Exclusion criteria
✕. Diagnosed as central nervous system lymphoma
✕. World health organization-Eastern Cooperative Oncology Group Performance tatus (ECOG) ≥2
✕. Other malignant tumor history or active malignant tumor need be treated
✕. Serious surgery and trauma less than two weeks
✕. Systemic therapy for serious acute/chronic infection
✕. Congestive heart failure, uncontrolled coronary heart disease, arrhythmia and heart infarction less than 6 months
What they're measuring
1
2-year progression-free survival
Timeframe: from the beginning day of the first cycle (each cycle is 21 days) of treatment to the date of confirmed progressive disease or death, whichever occurs first, up to 2 years after last patient's enrollment